ABBV ▼ -0.1% - AbbVie Inc. $ABBV - AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026 AbbVie shares edged down 0.1% today despite the company presenting new real-world evidence for VRAYLAR at Psych Congress 2026, suggesting the market had already priced in expectations around the antipsychotic treatment's clinical profile or investors focused on other factors affecting the stock. 18-SEP-2026 08:30 AM ET